Switching from Scheduled Haloperidol to Oral or LAI Formulation

Immediate Transition to Oral Formulation

Switch to oral haloperidol as soon as the acute agitation episode resolves, typically after 24-48 hours of controlled behavior, as recommended by the American Academy of Pediatrics and the American College of Clinical Pharmacology 1, 2
The patient can be directly converted to oral dosing, with a total daily dose given in divided doses, such as 5 mg PO twice daily or 2.5-5 mg PO three times daily, according to the American College of Clinical Pharmacology 1, 2
For elderly or frail patients, consider lower doses (0.5-1 mg) and titrate gradually, as suggested by the American Geriatrics Society 1
Monitor for continued behavioral control and adjust dosing based on response, with close attention to potential extrapyramidal symptoms (EPSs) and cardiovascular effects, as recommended by the American College of Emergency Physicians 1, 3

Assess for extrapyramidal symptoms (EPSs), which are common with haloperidol, and check QTc interval as haloperidol can prolong QT, according to the American Heart Association 1
Evaluate for orthostatic hypotension and other cardiovascular effects, as recommended by the American College of Cardiology 1, 3

Patients with Parkinson's disease or Lewy body dementia should not receive haloperidol due to EPS risk, as recommended by the American Academy of Neurology 1